SLCO1B1 and statin muscle symptoms

Statins lower LDL cholesterol and reduce the chance of heart attack and stroke in people at risk. Their effect is exerted mainly in the liver, so the amount that reaches muscle rather than liver is what drives side effects. Muscle problems are the most commonly reported adverse effect, according to the MHRA, though it describes them as generally mild and not medically serious.

The MHRA breaks the muscle problems into three levels, with rates per 100,000 patient-years: mild muscle pain 190, myopathy 5 and rhabdomyolysis 1.6. Rhabdomyolysis, the breakdown of muscle with kidney strain, is very rare, but the spectrum is why unexplained muscle symptoms deserve a prompt check.

MedlinePlus Genetics explains that the SLCO1B1 gene produces OATP1B1, a transporter on liver cells that pulls substances from the blood into the liver, including statins, bilirubin and hormones. The common V174A variant, found in about 15 per cent of people, reduces transport efficiency so statins build up in the bloodstream.

The MHRA describes three groups based on gene copies: normal (TT), intermediate (TC) and poor (CC). Poor-transport carriers had substantially reduced statin clearance, with the MHRA quoting 221 per cent higher simvastatin exposure compared with normal. For fluvastatin the difference was small and not significant, at 19 per cent. In short, the gene matters most for simvastatin, and less for some other statins.

• TT: normal transport and standard statin handling.

• TC: intermediate, with moderately raised levels.

• CC: poor transport, with the largest rise in simvastatin levels.

The MHRA lists dose as a factor, with risk rising as the statin dose increases, along with other medicines that either harm muscle themselves or increase statin blood levels. Examples in its interaction guidance include fibrates, ezetimibe and ciclosporin, and, for simvastatin and atorvastatin, drugs that block CYP3A4 such as itraconazole and clarithromycin. Grapefruit juice also raises levels.

The NHS simvastatin page says to avoid the medicine if you have unexplained ongoing muscle pain or a family history of muscle problems, and lists muscle toxicity with cramps, pain and weakness as a serious side effect. Genes are therefore only one thread, and often not the decisive one.

If you develop new muscle pain, tenderness or weakness on a statin, contact your GP or pharmacist rather than quietly stopping, because stopping removes protection against heart disease without a plan. The MHRA advises seeking medical attention for muscle problems and says the response may be a lower dose, a switch to another statin or discontinuation, based on severity and your cardiovascular risk.

Muscle pain with dark urine, severe weakness or fever needs urgent assessment through NHS 111 or A&E, as it can indicate rhabdomyolysis. Mild aches that start with exercise or illness are common and are worth mentioning at the review.

The test can describe your transporter group, and the information is consistent with the MHRA's explanation of exposure differences. But the MHRA's statin advice stresses clinical management, and a result seldom changes the first step, which is simply to review dose, interactions and drug choice. Whether a test is offered depends on the local service.

If you have had muscle problems on simvastatin, the pragmatic options include trying a different statin or a lower dose, and a pharmacist can talk through them. A result that suggests poor transport would make simvastatin, in particular, less attractive.

For people who have had a heart attack or stroke, or who have very high cholesterol, statins offer substantial protection, and the MHRA states that symptoms are generally mild. The aim of a gene-aware approach is to keep people on a tolerable statin rather than to stop treatment altogether.

If you cannot take statins at all, other cholesterol-lowering options exist, and your GP or cardiologist can discuss them.